Jacob Ark, MD
Urology · Saint Louis, MONPI 1891053716
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Dendreon Pharmaceuticals LLC at 44.4% of the total. Reporting peaked in 2022 at $8,190 and has fallen 79.7% since, to $1,666 in 2025. Among urology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $47.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$8K
- Neotract Inc.$2K
- Johnson & Johnson$1K
- Astellas Pharma US Inc$859
- Sumitomo Pharma America, Inc.$723
- Myriad Genetic Laboratories, Inc.$542
- plus $5K from 42 others
What the payments were for
- Consulting fees$5,95832%
- Travel & lodging$2,59514%
- Food & beverage$9,61252%
- Education$2251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$7,193
- UroLift$1,417
- Erleada$858
- Kerecis Omega3 SurgiClose$334
- UroLift System$285
- Prolaris$229
- AQUABEAM SYSTEM$190
- RYBREVANT$136
- CARVYKTI$136
- iTIND System$129
- XTANDI$125
- ZUSDURI$121
- Kerecis Omega3 GraftGuide$111
- Kerecis Omega3 Marigen$111
- LithoVue$102
How this compares
$18,389 in reported general payments places this provider in the 90th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 229 | $3,237,130 |
| NubeqaDarolutamide | 52 | $676,590 |
| ErleadaApalutamide | 30 | $409,884 |
| OrgovyxRelugolix | 68 | $204,770 |
| GemtesaVibegron | 63 | $54,562 |
| MyrbetriqMirabegron | 46 | $35,633 |
| Abiraterone Acetate | 24 | $28,049 |
| Tamsulosin Hcl | 179 | $2,690 |
| Finasteride | 219 | $2,586 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $728 |
| Trospium Chloride | 16 | $416 |
| NitrofurantoinNitrofurantoin Macrocrystal | 16 | $369 |
| Tadalafil | 20 | $238 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 16 | $205 |
| Oxycodone Hcl | 44 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $859 | $3,272,763275 claims |
| BayerNubeqa | $457 | $676,59052 claims |
| Johnson & JohnsonErleada | $1,232 | $409,88430 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $723 | $259,331131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 urology providers in Missouri.
Other urology in Saint Louis
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gurdarshan SandhuSaint Louis$101K
- Gregory McLennanSaint Louis$89K
- Gerald AndrioleSaint Louis$64K
- Charles JonesSaint Louis$55K
- Meredith MetcalfSaint Louis$26K
- Maung Htein ThuSaint Louis$22K
- Alexander ChowSaint Louis$20K
- Jonathan WeeseSaint Louis$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.